Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Sarath.Chandra@globaldata.com

  • Home
  • Author: Sarath.Chandra@globaldata.com

New Zealand credit and charge card payments market to reach nearly $40 billion in 2028, forecasts GlobalData

The New Zealand credit and charge card payments market is forecast to register a compound annual growth rate (CAGR) of 4.4% between 2024 and 2028 to reach NZD64.5 billion ($39.6 billion) in 2028, supported by the constant consumer shift towards electronic payments, according to GlobalData, a leading data and analytics company. GlobalData’s Payment Cards Analytics […]
Read more

Crypto hiring sentiment expected to stay strong following Donald Trump’s re-election, says GlobalData

Crypto hiring sentiments are expected to remain high, driven by the recent US election outcome. With Donald Trump returning to office, market optimism for a pro-crypto regulatory environment has been reignited. His stance is anticipated to provide regulatory clarity and foster industry growth, leading to an increase in hiring activity, particularly in compliance and regulatory […]
Read more

Insurance industry embraces data analytics to improve risk management, says GlobalData

The insurance industry is embracing technological advancements to enhance risk assessment, fraud detection, and customer insights. Insurance data analytics plays an essential role in improving decision-making and optimizing risk management, leveraging predictive modeling and machine learning to support more personalized services and regulatory compliance. The growing patent activity further highlights the industry’s shift towards innovative […]
Read more

Paratek Phase IIb results highlight omadacycline’s potential to address unmet needs in NTM treatment, says GlobalData

Paratek Pharmaceuticals has released positive topline data from a Phase IIb trial evaluating its oral antibiotic omadacycline in adult patients with nontuberculous mycobacterial (NTM) pulmonary disease. This first-ever, randomized, placebo-controlled trial among the Mycobacterium abscessus complex (MABc) patients, highlights omadacycline’s potential to fulfill a critical unmet need within the NTM market, says GlobalData, a leading […]
Read more

Food waste crisis accelerates sustainable practices across APAC food and beverage industry, says GlobalData

The escalating food waste crisis in the Asia-Pacific region presents a significant challenge that demands urgent attention from stakeholders across the supply chain. To combat this, foodservice operators are increasingly adopting recycling as a cornerstone of sustainable practices. Sustainability initiatives in the food and beverage industry include ethical sourcing, food waste reduction, and implementing composting […]
Read more

UCB and Biogen’s dapirolizumab pegol paves new path for systemic lupus erythematosus treatment, says GlobalData

UCB and Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. With a novel CD40L-targeting mechanism and favorable efficacy outcomes, this therapy has the potential to challenge established SLE treatments […]
Read more

Canada viscosupplementation market set to grow at over 7.5% CAGR through 2033, forecasts GlobalData

Osteoarthritis (OA) prevalence is on the rise in Canada, driven significantly by an aging population and increasing obesity rates. In response, viscosupplementation—injecting hyaluronic acid directly into the joints—has become a minimally invasive option to manage OA pain and potentially postpone more intensive interventions, like knee replacement surgery. Consequently, the Canada viscosupplementation market is set to […]
Read more

Parkinson’s disease clinical research in 7MM focuses on disease-modifying agents, says GlobalData

Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs). With current treatments largely focused on motor symptoms, the pipeline across the seven major markets (7MM*) highlights a growing emphasis on DMTs and non-motor symptom therapies, signaling a commitment to advancing PD treatments that address the full […]
Read more

Palantir Technologies strong Q3 2024 earnings and AI platform fuel influencer buzz on X, reveals GlobalData

Palantir Technologies delivered strong Q3 2024 earnings, surpassing expectations with a 30% year-over-year growth, including a notable 54% surge in US commercial revenue. The company’s focus on its artificial intelligence platform (AIP) has emerged as a key growth driver, with industry influencers highlighting its substantial role in accelerating revenue, fueling significant discussion and excitement on […]
Read more
1 … 46 47 48 49 50 … 209